Based on the "A+X" development strategy, Bluesail Medical has developed into a "multinational medical device comprehensive platform enterprise with China as the core and facing the world" along the "high, medium and low" medical device consumables tracks. At the beginning of its establishment, the company was mainly engaged in the production and sales of PVC gloves, and has now developed into four major divisions: cardiovascular and cerebrovascular division, protection division, nursing division and surgical division.
On the evening of October 30, the company disclosed its report for the third quarter of 2023. According to the report, the company's protection division still showed an operating loss of 1900 million yuan, but the loss in the third quarter showed a continuous and obvious narrowing trend following the previous two quarters, and the company's glove business showed signs of inflection point. Affected by this, this week, Bluesail Medical received 16 institutions for investigation.
The company made a detailed introduction to the glove business that investors are concerned about.
In terms of the operating performance of the glove business, the operating income and net profit of the company's glove business in the third quarter have improved significantly compared with the second quarter, the gross profit margin has increased significantly, from negative to positive, and the loss margin has continued to narrow.
In terms of production and sales, the comprehensive sales volume of glove products of the company's protective division in the first three quarters increased by more than 11% year-on-year, and the comprehensive production volume increased by nearly 15% year-on-year. Among them, the production capacity of nitrile gloves is about 23 billion, and the company has the ability to quickly adjust the production capacity according to the future development trend of the glove industry.
*, as sales increase, the company expects its products** to rise accordingly. According to the company's data, the ** of nitrile gloves has shown an upward trend since the second quarter of this year, although there will be a slight adjustment up and down in the past few months, but the overall trend is slow.
In addition, in terms of overseas markets, the company's sales in overseas markets are mainly ODM model, and compared with last year, there is no obvious change in the customer side.
For the future development of the glove business, the company said that the production line of Chinese manufacturers has a higher level of automation, production efficiency, and lower manpower, raw material and energy costs, and once the demand for gloves rebounds, Chinese glove factories can quickly expand production capacity, and then seize the global market share.